Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole in S. aureus Bacteremia
NCT00505258Phase 2
Key facts
- Status
- Withdrawn
- Sponsor
- Basilea Pharmaceutica
- Modality
- Reversible Covalent Inhibitors
- Conditions
- Staphylococcus aureus bacteremia (SAB)
01
Overview
Phase 2, randomised, open-label trial of ceftobiprole medocaril in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Time to bloodstream clearance of MRSA and MSSA. Status: withdrawn.
02
Design
2 arms- Study design
- RandomizedOpen-label
Ceftobiprole medocaril
Ceftobiprole 500 mg every 8 hours
Conventional Therapy
Standard of care comparator therapy
03
Who it enrols
Hospitalized patients with signs and symptoms of systemic staphylococcal infection, excluding those with catheter-related bacteremia, left-sided endocarditis, or recent prior antistaphylococcal therapy.
04
Endpoints
Primary
Time to bloodstream clearance of MRSA and MSSA
Secondary
Time to bloodstream clearance of MRSA and MSSA (Comparative)
Beyond the preview
Go deeper on NCT00505258.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505258.